Forty Seven

Gilead drug acquired in $5B buyout fails key blood cancer trial
BioPharma Dive
Mon, 07/24/23 - 11:47 am
Gilead Sciences
M&A
oncology
clinical trials
magrolimab
MDS
Forty Seven
Cancer biotech Pheast unveils $76M to expand immunotherapy’s menu to new targets
MedCity News
Wed, 04/27/22 - 10:51 am
startups
Pheast Therapeutics
Forty Seven
immunotherapy
Gilead taps brakes on $4.9B bet after rival's failure, pushing blood cancer data out to 2022
Fierce Biotech
Fri, 10/29/21 - 10:35 am
Gilead Sciences
Forty Seven
magrolimab
MDS
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
Tue, 01/19/21 - 10:30 am
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
Wed, 01/6/21 - 10:41 am
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
The top 5 pharma M&A deals of 2020
Pharmaforum
Mon, 12/21/20 - 11:07 am
M&A
AstraZeneca
Alexion
Gilead Sciences
Immunomedics
Forty Seven
JNJ
Momenta
Sanofi
Principia Biopharma
AbbVie has 47 reasons for its $2B cancer immunotherapy partnership with I-Mab
MedCity News
Sun, 09/6/20 - 07:19 pm
AbbVie
I-Mab Biopharma
Forty Seven
lemzoparlimab
cancer immunotherapy
Gilead trumpets data with newly-bought magrolimab in blood cancers
Pharmaforum
Sun, 05/31/20 - 11:53 pm
Gilead Sciences
ASCO 2020
Forty Seven
magrolimab
M&A
MDS
Biopharma acquisitions slow, but it's not Covid-19's fault yet
EP Vantage
Wed, 04/8/20 - 10:28 am
M&A
COVID-19
Gilead Sciences
Forty Seven
Eli Lilly
Dermira
Takeda
Hypera Pharma
ANI Pharmaceuticals
Amerigen Pharma
A Covid-19 threat to business acquisitions
EP Vantage
Thu, 04/2/20 - 11:57 am
COVID-19
M&A
AbbVie
Allergan
Arya Sciences
Immatics
AcelRx
Tetraphase
Gilead Sciences
Forty Seven
Thermo Fisher
Stryker
Wright Medical
Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia
Pharmaceutical Business Review
Thu, 03/12/20 - 11:01 am
Forty Seven
Rocket Pharmaceuticals
R&D
Fanconi Anemia
pediatric
Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?
Investors Business Daily
Sat, 03/7/20 - 07:41 pm
Gilead Scinecs
M&A
Forty Seven
immuno-oncology
Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug
Fierce Biotech
Mon, 03/2/20 - 10:13 am
Gilead Sciences
M&A
Forty Seven
CD-47
Gilead hungry for 'don't eat me' cancer biotech: reports
Fierce Biotech
Fri, 02/28/20 - 10:51 am
Gilead Sciences
Forty Seven
cancer
M&A
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Yahoo/Benzinga
Mon, 02/3/20 - 10:37 am
earnings
Forty Seven
Jounce Therapeutics
Catalyst Biosciences
Kodiak Sciences
Adverum Biotechnologies
IPOs
Beam Therapeutics
This Cancer Drug Is Driving Forty Seven's Stock Higher
Motley Fool
Mon, 01/27/20 - 10:56 pm
Forty Seven
magrolimab
clinical trials
myelodysplastic syndrome
Forty Seven bucks the trend
EP Vantage
Thu, 01/23/20 - 12:02 pm
Forty Seven
CD47
hematology
magrolimab
colorectal cancer
This Small-Cap Biotech Rose as Much as 98.3% Today
Motley Fool
Mon, 12/9/19 - 11:30 pm
Forty Seven
ASH2019
magrolimab
monoclonal antibodies
AML
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
Sun, 06/9/19 - 01:36 pm
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Wed, 05/15/19 - 11:52 pm
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven

Pages